Your browser doesn't support javascript.
loading
Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment.
Batchelder, Laurie; Philpott, Stephanie; Divino, Victoria; Boytsov, Natalie; Maiese, Eric M; Hogea, Cosmina; Buckingham, Trudy; Chen, Chi-Chang; Rodriguez, Ana Maria.
Afiliación
  • Batchelder L; IQVIA Patient Centered Solutions, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK.
  • Philpott S; IQVIA Patient Centered Solutions, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK.
  • Divino V; IQVIA US Medical and Scientific Services, Real World Evidence Solutions, 3110 Fairview Park Drive, Suite 400, Falls Church, VA 22042, USA.
  • Boytsov N; GlaxoSmithKline, Value Evidence and Outcomes, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
  • Maiese EM; GlaxoSmithKline, Value Evidence and Outcomes, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
  • Hogea C; GlaxoSmithKline, Value Evidence and Outcomes, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
  • Buckingham T; GlaxoSmithKline, Collaborative Real-World Evidence, 5 Moore Drive, Research Triangle Park, NC 27709, USA.
  • Chen CC; IQVIA US Medical and Scientific Services, Real World Evidence Solutions, 1 IMS Drive, Plymouth Meeting, PA 19462, USA.
  • Rodriguez AM; IQVIA Patient Centered Solutions, C. Juan Esplandiu, 11, Madrid, 28007, Spain.
Future Oncol ; 18(25): 2843-2856, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35801416
When deciding which treatment patients with relapsed or refractory multiple myeloma should receive, physicians have to weigh the benefits of each treatment against the risk of side effects. This study required physicians to complete a survey on aspects involved in their treatment decisions and identified those of highest importance. Physicians chose patient survival as the most important factor and minimization of side effects as less important considerations. Reducing patients' risk of developing corneal conditions or low platelet (a type of blood cell) count were of equal importance to doctors. Understanding physicians' treatment preferences and the reasons behind them will help identify gaps in education about new therapies as they become available.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Médicos / Mieloma Múltiple Tipo de estudio: Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Médicos / Mieloma Múltiple Tipo de estudio: Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido